Skip to main content
Erschienen in: CardioVascular and Interventional Radiology 8/2020

20.05.2020 | Clinical Investigation

Predictors of Occurrence and Risk of Hepatic Encephalopathy After TIPS Creation: A 15-Year Experience

verfasst von: Wendy Melissa Coronado, Connie Ju, Jennifer Bullen, Baljendra Kapoor

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify clinical variables, including use of newer Viatorr TIPS endoprosthesis with controlled expansion (VCX) that may affect the occurrence and risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) creation.

Methods

A total of 376 patients who underwent TIPS creation at our institution between 2003 and 2018 were retrospectively identified. Of these patients, 71 received a Viatorr controlled expansion endoprosthesis and 305 received a Viatorr TIPS endoprosthesis (older version without controlled expansion). Multivariate regression analysis was used to identify factors predicting the occurrence of hepatic encephalopathy after TIPS creation; a Cox proportional hazard model was used to assess risk of HE through time to HE onset

Results

A total of 194 patients (52%) developed hepatic encephalopathy after TIPS creation, including 28 of 71 patients (39%) who received a VCX endoprosthesis. Older patient age and the use of Viatorr endoprosthesis without controlled expansion were significantly associated with the development of hepatic encephalopathy overall. Pre-TIPS pressure variables, patient age, plasma international normalized ratio, and model for end-stage liver disease score were risk factors for time to hepatic encephalopathy.

Conclusion

Several variables are mild predictors of early hepatic encephalopathy development after TIPS creation, and the use of VCX endoprosthesis in TIPS creation is associated with a modest lower risk of hepatic encephalopathy. These preliminary findings should be considered in regard to patient selection, endoprosthesis selection, and post-transjugular intrahepatic portosystemic shunt creation monitoring for the development of hepatic encephalopathy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Casadaban LC, Parvinian A, Minocha J, et al. Clearing the confusion over hepatic encephalopathy after TIPS creation: incidence, prognostic factors, and clinical outcomes. Dig Dis Sci. 2015;60(4):1059–66.CrossRef Casadaban LC, Parvinian A, Minocha J, et al. Clearing the confusion over hepatic encephalopathy after TIPS creation: incidence, prognostic factors, and clinical outcomes. Dig Dis Sci. 2015;60(4):1059–66.CrossRef
2.
Zurück zum Zitat Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012;16(1):133–46.CrossRef Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012;16(1):133–46.CrossRef
3.
Zurück zum Zitat Lee EW, Kuei A, Saab S, et al. Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt. World J Gastroenterol. 2016;22(25):5780.CrossRef Lee EW, Kuei A, Saab S, et al. Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt. World J Gastroenterol. 2016;22(25):5780.CrossRef
4.
Zurück zum Zitat Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol. 2012;10(9):1034–1041.e1.CrossRef Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol. 2012;10(9):1034–1041.e1.CrossRef
5.
Zurück zum Zitat Bai M, Qi X, Yang Z, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients. J Gastroenterol Hepatol. 2011;26(6):943–51.CrossRef Bai M, Qi X, Yang Z, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients. J Gastroenterol Hepatol. 2011;26(6):943–51.CrossRef
6.
Zurück zum Zitat Merola J, Chaudhary N, Qian M, et al. Hyponatremia: a risk factor for early overt encephalopathy after transjugular intrahepatic portosystemic shunt creation. J Clin Med. 2014;3(4):359–72.CrossRef Merola J, Chaudhary N, Qian M, et al. Hyponatremia: a risk factor for early overt encephalopathy after transjugular intrahepatic portosystemic shunt creation. J Clin Med. 2014;3(4):359–72.CrossRef
7.
Zurück zum Zitat Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the study of liver diseases and the European association for the study of the liver. Hepatology. 2014;60(2):715–35.CrossRef Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the study of liver diseases and the European association for the study of the liver. Hepatology. 2014;60(2):715–35.CrossRef
8.
Zurück zum Zitat Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42(5):674–9.CrossRef Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42(5):674–9.CrossRef
9.
Zurück zum Zitat Luo X, Wang X, Zhu Y, et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with expanded polytetrafluoroethylene-covered stent-grafts: 8-mm versus 10-mm. Cardiovasc Intervent Radiol. 2019;42(5):737–43.CrossRef Luo X, Wang X, Zhu Y, et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with expanded polytetrafluoroethylene-covered stent-grafts: 8-mm versus 10-mm. Cardiovasc Intervent Radiol. 2019;42(5):737–43.CrossRef
10.
Zurück zum Zitat Schepis F, Vizzutti F, Garcia-Tsao G, et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis. Clin Gastroenterol Hepatol. 2018;16(7):1153–1162.e7.CrossRef Schepis F, Vizzutti F, Garcia-Tsao G, et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis. Clin Gastroenterol Hepatol. 2018;16(7):1153–1162.e7.CrossRef
11.
Zurück zum Zitat Pieper CC, Jansen C, Meyer C, et al. Prospective evaluation of passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stent grafts—a three-dimensional sonography study. J Vasc Interv Radiol. 2017;28(1):117–25.CrossRef Pieper CC, Jansen C, Meyer C, et al. Prospective evaluation of passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stent grafts—a three-dimensional sonography study. J Vasc Interv Radiol. 2017;28(1):117–25.CrossRef
12.
Zurück zum Zitat Miraglia R, Maruzzelli L, Di Piazza A, et al. Transjugular intrahepatic portosystemic shunt using the new gore Viatorr controlled expansion endoprosthesis: prospective, single-center preliminary experience. Cardiovasc Intervent Radiol. 2019;42(1):78–86.CrossRef Miraglia R, Maruzzelli L, Di Piazza A, et al. Transjugular intrahepatic portosystemic shunt using the new gore Viatorr controlled expansion endoprosthesis: prospective, single-center preliminary experience. Cardiovasc Intervent Radiol. 2019;42(1):78–86.CrossRef
13.
Zurück zum Zitat Flamm SL. Considerations for the cost-effective management of hepatic encephalopathy. Am J Manag Care. 2018;24(4 Suppl):S51–S61.PubMed Flamm SL. Considerations for the cost-effective management of hepatic encephalopathy. Am J Manag Care. 2018;24(4 Suppl):S51–S61.PubMed
14.
Zurück zum Zitat Pereira K, Carrion AF, Martin P, et al. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy. Liver Int. 2015;35(12):2487–94.CrossRef Pereira K, Carrion AF, Martin P, et al. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy. Liver Int. 2015;35(12):2487–94.CrossRef
15.
Zurück zum Zitat Peter P, Andrej Z, Katarina SP, Manca G, Pavel S. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage. Gastroenterol Res Pract. 2013;2013:398172.CrossRef Peter P, Andrej Z, Katarina SP, Manca G, Pavel S. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage. Gastroenterol Res Pract. 2013;2013:398172.CrossRef
16.
Zurück zum Zitat Rössle M, Euringer W. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. In: Mullen KD, Prakash RK, editors. Hepatic enceph. New York: Humana Press Inc; 2012. p. 211–220.CrossRef Rössle M, Euringer W. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. In: Mullen KD, Prakash RK, editors. Hepatic enceph. New York: Humana Press Inc; 2012. p. 211–220.CrossRef
17.
Zurück zum Zitat Kircheis G, Bode JG, Hilger N, Kramer T, Schnitzler A, Häussinger D. Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation. Eur J Gastroenterol Hepatol. 2009;21(12):1383–94.CrossRef Kircheis G, Bode JG, Hilger N, Kramer T, Schnitzler A, Häussinger D. Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation. Eur J Gastroenterol Hepatol. 2009;21(12):1383–94.CrossRef
18.
Zurück zum Zitat Yao J, Zuo L, An G, et al. Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma and portal hypertension. J Gastrointestin Liver Dis. 2015;24(3):301–7.CrossRef Yao J, Zuo L, An G, et al. Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma and portal hypertension. J Gastrointestin Liver Dis. 2015;24(3):301–7.CrossRef
19.
Zurück zum Zitat Hassoun Z, Deschênes M, Lafortune M, et al. Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy. Am J Gastroenterol. 2001;96(4):1205–9.CrossRef Hassoun Z, Deschênes M, Lafortune M, et al. Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy. Am J Gastroenterol. 2001;96(4):1205–9.CrossRef
20.
Zurück zum Zitat Kamath P, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.CrossRef Kamath P, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.CrossRef
21.
Zurück zum Zitat Bureau C, Métivier S, D’Amico M, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol. 2011;54(5):901–7.CrossRef Bureau C, Métivier S, D’Amico M, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol. 2011;54(5):901–7.CrossRef
22.
Zurück zum Zitat Guevara M, Baccaro ME, Ríos J, et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. 2010;30(8):1137–42.CrossRef Guevara M, Baccaro ME, Ríos J, et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. 2010;30(8):1137–42.CrossRef
23.
Zurück zum Zitat Deng D, Liao M-S, Qin J-P, Li X-A. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy. Hepatobiliary Pancreat Dis Int. 2006;5(2):232–6.PubMed Deng D, Liao M-S, Qin J-P, Li X-A. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy. Hepatobiliary Pancreat Dis Int. 2006;5(2):232–6.PubMed
24.
Zurück zum Zitat Afif AM, Chang JPE, Wang YY, et al. A sonographic Doppler study of the hepatic vein, portal vein and hepatic artery in liver cirrhosis: correlation of hepatic hemodynamics with clinical Child Pugh score in Singapore. Ultrasound. 2017;25(4):213–21.CrossRef Afif AM, Chang JPE, Wang YY, et al. A sonographic Doppler study of the hepatic vein, portal vein and hepatic artery in liver cirrhosis: correlation of hepatic hemodynamics with clinical Child Pugh score in Singapore. Ultrasound. 2017;25(4):213–21.CrossRef
25.
Zurück zum Zitat Perisic M, Ilic-Mostic T, Stojkovic M, Culafic D, Sarenac R. Doppler hemodynamic study in portal hypertension and hepatic encephalopathy. Hepatogastroenterology. 2005;52(61):156–60.PubMed Perisic M, Ilic-Mostic T, Stojkovic M, Culafic D, Sarenac R. Doppler hemodynamic study in portal hypertension and hepatic encephalopathy. Hepatogastroenterology. 2005;52(61):156–60.PubMed
26.
Zurück zum Zitat Boyer TD, Haskal ZJ. AASLD practice guideline update: the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. Hepatology. 2010;51(1):808–15.CrossRef Boyer TD, Haskal ZJ. AASLD practice guideline update: the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. Hepatology. 2010;51(1):808–15.CrossRef
27.
Zurück zum Zitat Rössle M, Siegerstetter V, Olschewski M, Ochs A, Berger E, Haag K. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts. Am J Gastroenterol. 2001;96(12):3379–83.CrossRef Rössle M, Siegerstetter V, Olschewski M, Ochs A, Berger E, Haag K. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts. Am J Gastroenterol. 2001;96(12):3379–83.CrossRef
28.
Zurück zum Zitat Hsieh Y-C, Lee K-C, Wang Y-W, et al. Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: role of ALBI score. PLoS ONE. 2018;13(12):e0208903.CrossRef Hsieh Y-C, Lee K-C, Wang Y-W, et al. Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: role of ALBI score. PLoS ONE. 2018;13(12):e0208903.CrossRef
29.
Zurück zum Zitat Sourianarayanane A, Talluri J, Humar A, McCullough AJ. Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2017;29(5):516–23.CrossRef Sourianarayanane A, Talluri J, Humar A, McCullough AJ. Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2017;29(5):516–23.CrossRef
30.
Zurück zum Zitat Merkel C, Montagnese S. Hepatic venous pressure gradient measurement in clinical hepatology. Digest Liver Dis. 2011;43(10):762–7.CrossRef Merkel C, Montagnese S. Hepatic venous pressure gradient measurement in clinical hepatology. Digest Liver Dis. 2011;43(10):762–7.CrossRef
31.
Zurück zum Zitat Srinivasa RN, Srinivasa RN, Chick JF, Hage A, Saad WA. Transjugular intrahepatic portosystemic shunt reduction using the GORE VIATORR controlled expansion endoprosthesis: hemodynamics of reducing an established 10-mm TIPS to 8-mm in diameter. Cardiovasc Intervent Radiol. 2018;41(3):518–21.CrossRef Srinivasa RN, Srinivasa RN, Chick JF, Hage A, Saad WA. Transjugular intrahepatic portosystemic shunt reduction using the GORE VIATORR controlled expansion endoprosthesis: hemodynamics of reducing an established 10-mm TIPS to 8-mm in diameter. Cardiovasc Intervent Radiol. 2018;41(3):518–21.CrossRef
32.
Zurück zum Zitat Francisco Rivera Ramos J, Rodríguez Leal C. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Ann Hepatol. 2011;10:S36–S3939.CrossRef Francisco Rivera Ramos J, Rodríguez Leal C. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Ann Hepatol. 2011;10:S36–S3939.CrossRef
33.
Zurück zum Zitat Kalaitzakis E, Josefsson A, Björnsson E. Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. BMC Gastroenterol. 2008;8(1):46.CrossRef Kalaitzakis E, Josefsson A, Björnsson E. Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. BMC Gastroenterol. 2008;8(1):46.CrossRef
Metadaten
Titel
Predictors of Occurrence and Risk of Hepatic Encephalopathy After TIPS Creation: A 15-Year Experience
verfasst von
Wendy Melissa Coronado
Connie Ju
Jennifer Bullen
Baljendra Kapoor
Publikationsdatum
20.05.2020
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 8/2020
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-020-02512-7

Weitere Artikel der Ausgabe 8/2020

CardioVascular and Interventional Radiology 8/2020 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.